Dr. Kaplan on the RELEVANCE Trial in Follicular Lymphoma

Lawrence D. Kaplan, MD
Published: Monday, Oct 08, 2018



Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

The combination of rituximab (Rituxan) and lenalidomide (Revlimid; R2) failed to meet its co-primary endpoint of progression-free survival versus rituximab and chemotherapy in the phase III RELEVANCE trial.

The superiority design of the trial was very ambitious, explains Kaplan. Though R2 missed its endpoint, Kaplan notes that the outcomes between the chemotherapy/rituximab regimens and the lenalidomide/rituximab regimen were very similar. This lends supports to the idea of using a non-chemotherapy regimen as frontline therapy. The regimen is a great treatment for patients with relapsed/refractory disease, according to Kaplan, who says that it currently serves as his standard second-line treatment. As time goes on, Kaplan predicts that this will become a favored approach for patients, especially those who may not be the best candidates for a chemotherapy-based regimen.
SELECTED
LANGUAGE


Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

The combination of rituximab (Rituxan) and lenalidomide (Revlimid; R2) failed to meet its co-primary endpoint of progression-free survival versus rituximab and chemotherapy in the phase III RELEVANCE trial.

The superiority design of the trial was very ambitious, explains Kaplan. Though R2 missed its endpoint, Kaplan notes that the outcomes between the chemotherapy/rituximab regimens and the lenalidomide/rituximab regimen were very similar. This lends supports to the idea of using a non-chemotherapy regimen as frontline therapy. The regimen is a great treatment for patients with relapsed/refractory disease, according to Kaplan, who says that it currently serves as his standard second-line treatment. As time goes on, Kaplan predicts that this will become a favored approach for patients, especially those who may not be the best candidates for a chemotherapy-based regimen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x